Substantial Shareholding (Regen Therapeutics)

Date : 06/19/2008 @ 12:26PM
Source : UK Regulatory (RNS and others)
Stock : Regen Therapeutics (RGT)
Quote : 12.5  0.0 (0.00%) @ 2:52AM
<< BackQuote Chart

 



Substantial Shareholding (Regen Therapeutics)

    RNS Number : 1421X
  ReGen Therapeutics PLC
  19 June 2008
   
 
19th June 2008
 
REGEN THERAPEUTICS PLC
(*ReGen* or the *Company*; Ticker: (RGT))
 
 
  TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES
 
 
1.       Identity of the issuer or the underlying issuer of existing shares to which voting
rights are attached (ii):
 
ReGen Therapeutics Plc
 
2.       Reason for the notification:
 
An acquisition or disposal of voting rights
 
3.       Full name of person(s) subject to the notification obligation (iii):
 
Andrew Clement Wilson
 
4.       Full name of shareholder(s) (if difference from 3):     
 
As above
 
5.       Date of the transaction and date on which the threshold is crossed or reached (v):
 
18 June 2008
 
6.       Date on which issued notified:
 
19 June 2008
 
7.       Threshold(s) that is/are crossed or reached:
 
13%


 



8.       Notified details 

 
A: Voting rights attached to shares
 
                   Class/type of share if possible using the ISIN Code                
GB00B28XMY25
 
                   Situation Previous to the triggering transaction (vi) *
                                  Number of Shares                                            
     1,477,000              
                                  Number of Voting Rights (viii)                              
  1,477,000              
 
                   Resulting situation after the triggering transaction (viii) *
                                  Number of Shares                                            
     1,495,000
                                  Number of Voting Rights * Direct (x)                    
1,495,000
                                  Number of Voting Rights * Indirect (xi)                 
N/A
                                  % of voting rights * Direct                                 
   13.02%
                                  % of voting rights * Indirect                               
   N/A                                      


 



 



B: Financial Instruments

Resulting situation after the triggering transaction (xii)
 
Type of financial instrument                                                   N/A
 
Expiration date (xiii)                                                              N/A
 
Exercise/Conversion Period/Date (xiv)                                   N/A
 
Number of voting rights that may be acquired if the
instrument is exercised/converted                                           N/A
 
% of voting rights                                                                  N/A


 

            Total (A+B)
 
Number of voting rights                                                               
1,495,000
 
% of voting rights                                                                       
13.02


 



 

9.       Chain of controlled undertakings through which the voting rights and/or the financial
instruments are effectively held, if
applicable (xv):
 
Shares are held in own name
 
Proxy Voting:
 
10.   Name of the proxy holder:                                                               
        N/A
 
11.   Number of voting rights proxy holder will cease to hold:                            
N/A
 
12.   Date on which proxy holder will cease to hold voting rights:                        N/A
 
13.   Additional information:                                                                 
           N/A
 
14.   Contact name:                                                                           
             N/A
 
15.   Contact telephone number:                                                               
       N/A


 

 
 
For further information:
 
Percy Lomax
ReGen Therapeutics Plc
Tel:                                                                  +44 (0) 207 153 4920
 
Roland Cornish / Felicity Geidt
Beaumont Cornish Limited
Tel:                                                                 +44(0) 207 628 3396



This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCFKCKDABKDCAD
<< Back


Regen Therapeutics Historical Chart Regen Therapeutics Intraday Chart  
Period


LSE and PLUS quotes are live. NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions :: Contact Us :: Request an Exchange :: Affiliate Scheme
Copyright1999-2008 ADVFN PLC. Copyright and limited reproduction :: Privacy Policy :: Investment Warning :: Advertise with us :: Data accreditations :: Investor Relations :: Press office :: Jobs
ADDITIONAL SERVICES AVAILABLE FROM ADVFN
Upgrade - Click here for more information on ADVFN premium services Money Words - ADVFN Financial Glossary Investor Training ADVFN Financial Bookshop Online Training Academy
30 site:2us 080907 12:11 Stock Message Boards ( 2001 | 2002 | 2003 | 2004 | 2005 | 2005 | 2007 )